Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: In patients with HCM at high risk of SCD, an ICD should be considered as a standard of care. Current risk approximation algorithms recommended by ESC 2014 criteria indicate that SCD risk is not stable. The aim of the study was to investigate how the calculated SCD risk in HCM patients with an ICD implanted in the past changed over time. Methods: We analyzed 64 HCM patients with ICD for primary prevention, referred for ICD re-implantation, and 32 HCM patients referred for a first-time ICD placement during the same period. The 5-year-SCD risk was assessed for suitable patients using the recommended ESC calculator. Results: The first-time group had a higher 5-year-SCD risk than those referred for ICD re-implantation: 7.50 (IQR 5.98−10.46) vs. 4.88 (IQR 3.42−7.25), p < 0.05. Out of the patients with an initial calculated risk below 4%, the risk increased in 22% of cases, reaching the 4−6% range. In 78% of patients, the risk remained stable and low. In 31% of patients with an initial calculated SCD risk ≥ 6%, the risk decreased over time to below 6%, and in 14% of the cases, below 4%. Conclusions: SCD risk in HCM patients is usually stable or gets lower. Our data suggest it is important to re-evaluate the risk profile for patients with HCM when ICD re-implantation is considered.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954740PMC
http://dx.doi.org/10.3390/jcm11061633DOI Listing

Publication Analysis

Top Keywords

hcm patients
20
scd risk
16
risk
14
icd re-implantation
12
patients
11
patients hcm
8
recommended esc
8
calculated scd
8
risk hcm
8
patients icd
8

Similar Publications

Apical hypertrophic cardiomyopathy (ApHCM) is an uncommon, nonobstructive form of hypertrophic cardiomyopathy (HCM) that is associated with an increased risk of ventricular aneurysms, atrial fibrillation, heart failure, and cardiac death. In this case report, a 63-year-old male patient was found to have deeply negative T waves on electrocardiogram (EKG) during a routine preoperative evaluation in an outpatient internal medicine clinic. Imaging with echocardiography and cardiac magnetic resonance confirmed the diagnosis of ApHCM.

View Article and Find Full Text PDF

Objective: This study sought to identify key prognostic factors in patients with hypertrophic cardiomyopathy (HCM) and heart failure with preserved ejection fraction (HFpEF), emphasizing the prognostic role of free triiodothyronine (FT3) levels.

Research Design And Methods: This retrospective cohort study enrolled 992 HCM-HFpEF patients from two Chinese medical centers between 2009 and 2019, excluding those with thyroid-affecting medications or disorders. Data on demographic and clinical variables, including FT3, were analyzed using univariate and multivariate Cox regression, Kaplan-Meier (KM) survival analysis, and restricted cubic spline (RCS) analysis to explore prognostic factors and FT3's nonlinear predictive value.

View Article and Find Full Text PDF

Background: Co-occurrence of type 2 diabetes mellitus (T2DM) and heart failure (HF) elevates the risk of morbidity and mortality. Recent research emphasizes treatment strategies that go beyond glycemic control to enhance heart function.

Aim: To assess the effectiveness and safety of the fixed-drug combination of dapagliflozin and sitagliptin (FDC D/S) in T2DM patients with HF.

View Article and Find Full Text PDF

Abstract: Hypertrophic cardiomyopathy (HCM) is a common hereditary heart disease and is the leading cause of sudden cardiac death in adolescents. Septal hypertrophy (SH) and apical hypertrophy (AH) are two common types. The former is characterized by abnormal septal myocardial thickening and the latter by left ventricular apical hypertrophy, both of which significantly increase the risk of heart failure, arrhythmias, and other serious complications.

View Article and Find Full Text PDF

Objective: To evaluate the impact of CT planning on surgical myectomy outcomes in patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) and/or mid-cavity obstruction, by comparing these outcomes with those of conventional surgical myectomy.

Methods: This prospective cohort study included patients who underwent surgical septal myectomy for HCM with LVOT and/or mid-cavity obstruction between January 2019 and May 2024 at a single tertiary center. In the CT-planned myectomy group, an expert radiologist simulated the target myectomy site through a series of post-processing methods to plan the surgical approach, provide a surgeon's view that closely resembles the actual perspective in the operating room, and present the target myectomy volume.

View Article and Find Full Text PDF